MDGL
Madrigal Pharmaceuticals Inc.
$571.44
+$0.11(+0.02%)
53
Overall
40
Value
72
Tech
47
Quality
Market Cap
$12.58B
Volume
177.49K
52W Range
$265.00 - $605.00
Target Price
$541.69
Company Overview
| Mkt Cap | $12.58B | Price | $571.44 |
| Volume | 177.49K | Change | +0.02% |
| P/E Ratio | -27.0 | Open | $570.11 |
| Revenue | $180.1M | Prev Close | $571.33 |
| Net Income | $-465.9M | 52W Range | $265.00 - $605.00 |
| Div Yield | N/A | Target | $541.69 |
| Overall | 53 | Value | 40 |
| Quality | 47 | Technical | 72 |
No chart data available
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
Shalu Saraf•6 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $571.44 | +0.0% | 177.49K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW